INCB018424

DRUG3 trials

Sponsors

Incyte Corporation, M.D. Anderson Cancer Center, Aaron R. Mangold

Conditions

Acute Lymphocytic LeukemiaAcute Myeloid LeukemiaChronic Myelogenous LeukemiaLichen PlanusMyelodysplastic SyndromeRheumatoid Arthritis

Phase 2

A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis

CompletedNCT00550043

Incyte CorporationRheumatoid Arthritis

Start: 2007-10-31End: 2008-09-30Updated: 2015-03-23

INCB018424 in Patients With Advanced Hematologic Malignancies

CompletedNCT00674479

M.D. Anderson Cancer CenterAcute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia +1

Start: 2008-05-12End: 2017-03-23Updated: 2025-06-15

Topical Ruxolitinib Lichen Planus

CompletedNCT03697460

Aaron R. MangoldLichen Planus

Start: 2018-08-30End: 2020-08-25Updated: 2021-08-04

Related Papers

Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis

Frontiers in Immunology2021-02-1520 citations

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.

2012-03-15162 citations